Compare IVA & SSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVA | SSYS |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.2M | 865.5M |
| IPO Year | 2020 | 1994 |
| Metric | IVA | SSYS |
|---|---|---|
| Price | $6.52 | $11.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 2 |
| Target Price | ★ $16.00 | $12.75 |
| AVG Volume (30 Days) | 414.1K | ★ 1.2M |
| Earning Date | 09-29-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,929,536.00 | ★ $561,461,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.11 | $8.12 |
| 52 Week High | $7.98 | $12.88 |
| Indicator | IVA | SSYS |
|---|---|---|
| Relative Strength Index (RSI) | 78.22 | 66.54 |
| Support Level | $4.48 | $9.94 |
| Resistance Level | $5.17 | $10.66 |
| Average True Range (ATR) | 0.25 | 0.55 |
| MACD | 0.19 | 0.19 |
| Stochastic Oscillator | 94.28 | 71.27 |
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Stratasys Ltd is a polymer-based 3D printing solution, which provides a product life cycle, with multiple technologies and complete solutions for superior application fit, across industrial, healthcare, and consumer fields. It focuses, in particular, on polymer 3D printing solutions that address the fastest-growing manufacturing solutions viewed as the potential growth opportunity in the 3D printing industry. Its printers include FDM, PolyJet, Stereolithography, P3, and SAF. Its software is GrabCAD Software, Connectivity, Digital Anatomy Creator, and OpenAM Software. It generates revenue through 3D printing systems, related services, and consumables and by providing additive manufacturing solutions.